This article has been updated to correct information about a study presented at ASCO. GenomeWeb regrets the error.
NEW YORK – Following the results of a validation study led by researchers at the European Institute of Oncology in Milan, clinical stage pharmaceutical firm Tiziana Life Sciences plans to demerge its genomics-based personalized medicine business into a spinoff company focused on breast cancer recurrence prediction.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
